Mumbai - India's Dr. Reddy's Labs posted a 49 percent growth in its third quarter revenues at 18.40 billion rupees ($379 million) with strong sales coming from its generic versions of anti-migraine drug Imitrex (sumatriptan succinate) in the U.S. Dr. Reddy's registered an after tax profit of 1.92 billion rupees ($ 40 million) for the same period against a loss of $ 25 million for the third quarter of 2008
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing
In this week's episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project.
Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.
